Top

Published in:

24-01-2024 | Letrozole | Review

Neoadjuvant endocrine treatment in hormone receptor-positive breast cancer: Does it result in more breast-conserving surgery?

Authors: Merel E. van de Loo, Layla Andour, Anne E. van Heesewijk, Hendrika M. Oosterkamp, Gerrit-Jan Liefers, Marieke E. Straver

Published in: Breast Cancer Research and Treatment | Issue 1/2024

Abstract

Background

Patients with locally advanced endocrine positive tumors who will not benefit from chemotherapy can be treated by either primary surgery or neoadjuvant endocrine therapy (NET). How often does NET result in breast-conserving surgery (BCS)?

Methods

We conducted a literature search in PubMed and Embase, to identify articles on surgical treatment after NET.

Results

In 19 studies the pathological complete response (pCR) rate was reported after NET; an overall pCR rate of 1% was found. Compared with neoadjuvant chemotherapy (NCT), the BCS rate was significantly higher after NET (OR 0.60; 95% CI, 0.51–0.69; P < 0.00001). The surgical conversion rate was reported in eight studies [4–75.9%], with a mean of 30.2%.

Conclusion

This review found that one out of three patients becomes eligible for BCS after treatment with NET.

Available only for authorised users

Burstein HJ et al (2010) American society of clinical oncology clinical practice guideline update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Oncol Pract 6(5):243–246PubMedPubMedCentral

Dunnwald LK, Rossing MA, Li CI (2007) Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res 9(1):R6PubMedPubMedCentral

Perloff M, Lesnick GJ (1982) Chemotherapy before and after mastectomy in stage III breast cancer. Arch Surg 117(7):879–881PubMed

Schick P et al (1983) Preoperative chemotherapy followed by mastectomy for locally advanced breast cancer. J Surg Oncol 22(4):278–282PubMed

Fisher B et al (1997) Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15(7):2483–2493PubMed

Mauriac L et al (1991) Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Results of a randomized trial in a single centre. Ann Oncol 2(5):347–354PubMed

Mauriac L et al (1999) Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonié Bordeaux Groupe Sein (IBBGS) 10(1):47–52

Semiglazov VF et al (2007) Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer. Cancer 110(2):244–254PubMed

Cardoso F et al (2016) 70-gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med 375(8):717–729PubMed

10.

Sparano JA et al (2018) Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med 379(2):111–121PubMedPubMedCentral

11.

Reis J et al (2020) Accuracy of breast MRI in patients receiving neoadjuvant endocrine therapy: comprehensive imaging analysis and correlation with clinical and pathological assessments. Breast Cancer Res Treat 184(2):407–420PubMedPubMedCentral

12.

Chiba A et al (2017) Trends in neoadjuvant endocrine therapy use and impact on rates of breast conservation in hormone receptor-positive breast cancer: a national cancer data base study. Ann Surg Oncol 24(2):418–424PubMed

13.

Yalcin B (2013) Overview on locally advanced breast cancer: defining, epidemiology, and overview on neoadjuvant therapy. Exp Oncol 35(4):250–252PubMed

14.

Higgins JPT et al (2011) The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 343:d5928PubMedPubMedCentral

15.

Sterne JA et al (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 355:i4919PubMedPubMedCentral

16.

von Elm E et al (2014) The strengthening the reporting of observational studies in epidemiology (STROBE) Statement: guidelines for reporting observational studies. Int J Surg 12(12):1495–1499

17.

Bennett JA (2005) The consolidated standards of reporting trials (CONSORT): guidelines for reporting randomized trials. Nurs Res 54(2):128–132PubMed

18.

Gazet JC et al (1996) Assesssment of the effect of pretreatment with neoadjuvant therapy on primary breast cancer. Br J Cancer 73(6):758–762PubMedPubMedCentral

19.

Pariser AC et al (2019) Utilization, duration, and outcomes of neoadjuvant endocrine therapy in the United States. Breast Cancer Res Treat 178(2):419–426PubMed

20.

Alba E et al (2012) Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study. Ann Oncol 23(12):3069–3074PubMed

21.

Cottu P et al (2018) Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer. Ann Oncol 29(12):2334–2340PubMed

22.

Dellapasqua S et al (2019) Neoadjuvant Degarelix versus triptorelin in premenopausal patients who receive letrozole for locally advanced endocrine-responsive breast cancer: a randomized phase II trial. J Clin Oncol 37(5):386–395PubMed

23.

Eiermann W et al (2001) Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 12(11):1527–1532PubMed

24.

Ellis MJ et al (2011) Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype–ACOSOG Z1031. J Clin Oncol 29(17):2342–2349PubMedPubMedCentral

25.

Grassadonia A et al (2014) Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer. Ann Surg Oncol 21(5):1575–1582PubMedPubMedCentral

26.

Hojo T et al (2013) Use of the neo-adjuvant exemestane in post-menopausal estrogen receptor-positive breast cancer: a randomized phase II trial (PTEX46) to investigate the optimal duration of preoperative endocrine therapy. Breast 22(3):263–267PubMed

27.

Johnston S et al (2019) Randomized phase II study evaluating palbociclib in addition to letrozole as neoadjuvant therapy in estrogen receptor-positive early breast cancer: PALLET trial. J Clin Oncol 37(3):178–189PubMed

28.

Kim HJ et al (2020) Efficacy of neoadjuvant endocrine therapy compared with neoadjuvant chemotherapy in pre-menopausal patients with oestrogen receptor-positive and HER2-negative, lymph node-positive breast cancer. Breast Cancer Res 22(1):54PubMedPubMedCentral

29.

Krainick-Strobel UE et al (2008) Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: a phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy. BMC Cancer 8:62PubMedPubMedCentral

30.

LeVasseur N et al (2019) Efficacy of neoadjuvant endocrine therapy versus neoadjuvant chemotherapy in ER-positive breast cancer: results from a prospective institutional database. Clin Breast Cancer 19(6):e683–e689PubMed

31.

Marcus DM et al (2013) Neoadjuvant hormonal therapy is associated with comparable outcomes to neoadjuvant chemotherapy in post-menopausal women with estrogen receptor-positive breast cancer. Front Oncol 3:317PubMedPubMedCentral

32.

Milla-Santos A et al (2004) Anastrozole as neoadjuvant therapy for patients with hormone-dependent, locally-advanced breast cancer. Anticancer Res 24(2C):1315–1318PubMed

33.

Palmieri C et al (2014) NEOCENT: a randomised feasibility and translational study comparing neoadjuvant endocrine therapy with chemotherapy in ER-rich postmenopausal primary breast cancer. Breast Cancer Res Treat 148(3):581–590PubMed

34.

Prat A et al (2020) Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol 21(1):33–43PubMed

35.

Quenel-Tueux N et al (2015) Clinical and genomic analysis of a randomised phase II study evaluating anastrozole and fulvestrant in postmenopausal patients treated for large operable or locally advanced hormone-receptor-positive breast cancer. Br J Cancer 113(4):585–594PubMedPubMedCentral

36.

Smith IE et al (2005) Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 23(22):5108–5116PubMed

37.

Thomas JS et al (2007) Histopathology of breast carcinoma following neoadjuvant systemic therapy: a common association between letrozole therapy and central scarring. Histopathology 51(2):219–226PubMed

38.

Thornton MJ et al (2019) Neoadjuvant endocrine therapy versus neoadjuvant chemotherapy in node-positive invasive lobular carcinoma. Ann Surg Oncol 26(10):3166–3177PubMedPubMedCentral

39.

Wright JL et al (2017) Locoregional and overall recurrence after neaodjuvant endocrine therapy versus chemotherapy in postmenopausal women with estrogen receptor+ HER2- breast cancer. Am J Clin Oncol 40(5):490–497PubMed

40.

Spring LM et al (2016) Neoadjuvant endocrine therapy for estrogen receptor-positive breast cancer: a systematic review and meta-analysis. JAMA Oncol 2(11):1477–1486PubMedPubMedCentral

41.

Cortazar P et al (2014) Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 384(9938):164–172PubMed

42.

Kaufmann M et al (2006) Recommendations from an international expert panel on the use of neoadjuvant (Primary) systemic treatment of operable breast cancer: an update. J Clin Oncol 24(12):1940–1949PubMed

43.

Ma CX et al (2017) NeoPalAna: neoadjuvant palbociclib, a cyclin-dependent kinase 4/6 inhibitor, and Anastrozole for clinical stage 2 or 3 estrogen receptor-positive breast cancer. Clin Cancer Res 23(15):4055–4065PubMedPubMedCentral

Title: Neoadjuvant endocrine treatment in hormone receptor-positive breast cancer: Does it result in more breast-conserving surgery?
Authors: Merel E. van de Loo
Layla Andour
Anne E. van Heesewijk
Hendrika M. Oosterkamp
Gerrit-Jan Liefers
Marieke E. Straver
Publication date: 24-01-2024
Publisher: Springer US
Keywords: Letrozole
Anastrozole
Exemestane
Breast Cancer
Breast Cancer
Tamoxifen
Cytostatic Therapy
Mastectomy
Published in: Breast Cancer Research and Treatment / Issue 1/2024
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-023-07222-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2024

Omission of axillary lymph node dissection for breast cancer patients with three or more positive sentinel lymph nodes

Real-world treatment patterns and clinical outcomes in patients treated with eribulin after prior phosphoinositide 3-Kinase inhibitor treatment for metastatic breast cancer

Socio-cultural and financial issues against breast cancer screening behaviour among eligible Indian women: evidence for action

Real-world use of multigene signatures in early breast cancer: differences to clinical trials

Randomized placebo-controlled, double-blind clinical trial of nanoemulsion curcumin in women with aromatase inhibitor-induced arthropathy: an Alliance/NCORP pilot trial

Trastuzumab and first-line taxane chemotherapy in metastatic breast cancer patients with a HER2-negative tumor and HER2-positive circulating tumor cells: a phase II trial

Keynote webinar | Spotlight on antibody–drug conjugates in cancer